Sugi Predict

Sugi Predict / Targets / RHEB

RHEB

GTP-binding protein Rheb · Q15382 · RHEB on Sugi Atlas →

11,105 patent compounds predicted against RHEB, 5,619 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL73057 SCHEMBL73057 0.61 11/20
SCHEMBL2003368 SCHEMBL2003368 0.59 11/20
SCHEMBL1022450 SCHEMBL1022450 0.58 11/20
SCHEMBL2116708 SCHEMBL2116708 0.51 10/20
SCHEMBL879761 SCHEMBL879761 0.44 10/20
SCHEMBL1144772 SCHEMBL1144772 0.63 9/20
SCHEMBL830446 SCHEMBL830446 0.50 9/20
SCHEMBL1020339 SCHEMBL1020339 0.50 9/20
SCHEMBL276034 SCHEMBL276034 0.47 9/20
SCHEMBL147290 SCHEMBL147290 0.46 9/20
SCHEMBL317600 SCHEMBL317600 0.43 9/20
SCHEMBL2007768 SCHEMBL2007768 0.43 9/20
SCHEMBL1641310 SCHEMBL1641310 0.42 9/20
SCHEMBL1642149 SCHEMBL1642149 0.42 9/20
SCHEMBL97760 SCHEMBL97760 0.40 9/20
SCHEMBL727389 SCHEMBL727389 0.76 8/20
SCHEMBL613213 SCHEMBL613213 0.52 8/20
SCHEMBL827753 SCHEMBL827753 0.50 8/20
SCHEMBL1020404 SCHEMBL1020404 0.50 8/20
SCHEMBL1020747 SCHEMBL1020747 0.50 8/20

Clinical trials — most relevant to RHEB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer PHASE2RECRUITING
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction EARLY_PHASE1RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy nanRECRUITING
Intermittent Fasting for Pancreatitis nanNOT_YET_RECRUITING
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Prehabilitation in Older People Undergoing Total Hip Replacement nanNOT_YET_RECRUITING
Identification of New Biomarkers of Insulin Resistance nanACTIVE_NOT_RECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Time Course for Fasting-induced Autophagy in Humans nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a RHEB binder may also engage these)

ProteinNameSimilarity
Q62639 — 1.000 Q62639 →
Q56JV3 — 1.000 Q56JV3 →
Q921J2 — 1.000 Q921J2 →
Q6P632 — 0.910 Q6P632 →
P61599 — 0.909 P61599 →
Q2PFM2 — 0.909 Q2PFM2 →
RALA Ras-related protein Ral-A 0.909 landscape →
Q58ED9 — 0.908 Q58ED9 →
P61600 — 0.908 P61600 →
Q7ZXR3 — 0.908 Q7ZXR3 →
P63320 — 0.907 P63320 →
P63321 — 0.907 P63321 →
P63322 — 0.907 P63322 →
PRKG1 cGMP-dependent protein kinase 1 0.906 landscape →
P00516 — 0.904 P00516 →
P0C605 — 0.903 P0C605 →
Q3MHL3 — 0.902 Q3MHL3 →
Q6P3H7 — 0.902 Q6P3H7 →
WDR5 WD repeat-containing protein 5 0.902 landscape →
Q9W7I5 — 0.901 Q9W7I5 →
RBBP4 Histone-binding protein RBBP4 0.899 landscape →
Q60972 — 0.899 Q60972 →
O35900 — 0.899 O35900 →
Q5RF92 — 0.899 Q5RF92 →
P61965 — 0.898 P61965 →
Q498M4 — 0.898 Q498M4 →
Q5M7K4 — 0.898 Q5M7K4 →
Q9Y333 — 0.898 Q9Y333 →
Q3ZBL0 — 0.898 Q3ZBL0 →
P62308 — 0.897 P62308 →